Dimerix Ltd has released a press release.
Appendix 4C and Quarterly Highlights
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Dimerix
- Dimerix Receives R&D Tax Cash Rebate Totalling $1.07m
- 1st Patient Dosed in DMX-200 Clinical Trial for FSGS
- DXB Receives Orphan Drug Designation in EU
- First patient dosed in dmx-200 clinical trial
- Executive team bolstered through CEO & md appointment
Later from Dimerix
- Appendix 4C - quarterly
- DMX-200 Manufacturing Update
- Dimerix Signs Licence Agreement for Receptor-HIT Technology
- DMX-200 Clinical Update
- DMX-200 Phase 2 Clinical Trial in FSGS Fully Recruited
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix